Lucepod CV Tablet is a combination antibiotic formulation containing Cefpodoxime Proxetil 200 mg and Clavulanic Acid 125 mg, designed for the treatment of a broad spectrum of bacterial infections. Cefpodoxime Proxetil, a third-generation oral cephalosporin, exhibits bactericidal activity by inhibiting bacterial cell wall synthesis, thereby effectively targeting Gram-positive and Gram-negative pathogens. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of Cefpodoxime by preventing enzymatic degradation of the antibiotic, particularly against beta-lactamase producing resistant strains. This synergistic combination is indicated for respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media, among others. Lucepod CV Tablet is administered orally and is well-absorbed with a favorable pharmacokinetic profile, ensuring adequate tissue penetration. The safety profile is consistent with cephalosporin antibiotics, with common adverse effects including gastrointestinal disturbances, hypersensitivity reactions, and occasional candidiasis. Caution is advised in patients with a history of penicillin or cephalosporin allergy. Dosage should be individualized based on infection severity, patient age, and renal function. Lucepod CV Tablet provides an effective therapeutic option for managing resistant bacterial infections, contributing to improved clinical outcomes when used as per medical guidance.